Claims
- 1. Mac-1 alpha-subunit, or a functional derivative thereof, substantially free of natural contaminants.
- 2. The Mac-1 alpha-subunit or said functional derivative thereof of claim 1, wherein said Mac-1 alpha-subunit is additionally capable of binding to a molecule present on the surface of a cell.
- 3. The Mac-1 alpha-subunit of claim 2, wherein said molecule present on the surface of a cell is iC3b or another natural ligand of Mac-1.
- 4. The Mac-1 alpha-subunit of claim 1, wherein said molecule is capable of associating with a Mac-1 beta subunit to form a Mac-1 heterodimer.
- 5. The Mac-1 alpha-subunit of claim 4, wherein said heterodimer is capable of binding iC3b or another natural ligand of Mac-1.
- 6. The Mac-1 alpha-subunit molecule of claim 2, wherein said molecule additionally contains at least one polypeptide selected from the group consisting of:
a. A-N-Q-R-G-S-L; b. M-E-Q-L-K-K-S; c. T-D-G-E-K-F-G; d. G-V-F-L-Y-T-S; e. V-D-V-D-S-S-N-G-S-T; f. D-V-N-G-D-K-L-T-D-V-A; g. D-L-T-M-D-G-L-V-D-L; h. Y-I-L-T-S-H-N; i. C-Q-D-D-L-S-I; j. T-I-Q-N-Q-L-R; k. V-Q-S-L-V-L-G; l. Y-Q-H-I-G-L-V; m. L-F-T-A-L-F-P; and n. F-S-L-V-G-T-P;
- 7. The functional derivative of the Mac-1 alpha-subunit of claim 2 wherein said functional derivative is a fragment of the Mac-1 alpha-subunit.
- 8. The functional derivative of the Mac-1 alpha-subunit of claim 2 wherein said functional derivative is a variant of Mac-1 alpha-subunit.
- 9. The functional derivative of the Mac-1 alpha-subunit of claim 2 wherein said functional derivative is an analog of Mac-1 alpha-subunit.
- 10. The functional derivative of the Mac-1 alpha-subunit of claim 2 wherein said functional derivative is a chemical derivative of Mac-1 alpha-subunit.
- 11. A recombinant DNA molecule capable of expressing Mac-1 alpha-subunit or a functional derivative thereof.
- 12. The DNA molecule of claim 11, wherein said Mac-1 alpha-subunit or said functional derivative thereof contains at least one poly-peptide selected from the group consisting of:
a. A-N-Q-R-G-S-L; b. M-E-Q-L-K-K-S; c. T-D-G-E-K-F-G; d. G-V-F-L-Y-T-S; e. V-D-V-D-S-S-N-G-S-T; f. D-V-N-G-D-K-L-T-D-V-A; g. D-L-T-M-D-G-L-V-D-L; h. Y-I-L-T-S-H-N; i. C-Q-D-D-L-S-I; j. T-I-Q-N-Q-L-R; k. V-Q-S-L-V-L-G; l. Y-Q-H-I-G-L-V; m. L-F-T-A-L-F-P; and n. F-S-L-V-G-T-P;
- 13. The Mac-1 alpha molecule or functional derivative thereof produced by expression of the recombinant molecule of claim 11.
- 14. A method for treating inflammation resulting from a response of the non-specific defense system in a mammalian subject which comprises providing to a subject in need of such treatment an anti-inflammatory agent, in an amount sufficient to suppress said inflammation; wherein said anti-inflammatory agent is selected from the group consisting of: the Mac-1 alpha-subunit; and a functional derivative of the Mac-1 alpha-subunit.
- 15. The method of claim 14 wherein said anti-inflammatory agent is the Mac-1 alpha-subunit.
- 16. The method of claim 14 wherein said anti-inflammatory agent is a functional derivative of the Mac-1 alpha-subunit.
- 17. The method of claim 14 which additionally comprises the administration of the Mac-1 beta-subunit or a functional derivative of the Mac-1 beta-subunit.
- 18. The method of claim 17 wherein said Mac-1 alpha subunit is produced by the expression of recombinant nucleic acid molecule and wherein said Mac-1 alpha subunit is associated with said beta subunit to thereby form a Mac-1 heterodimer.
- 19. The method of claim 14 wherein said anti-inflammatory agent is provided to said subject prior to the initiation of said inflammation.
- 20. The method of claim 14 wherein said anti-inflammatory agent is administered by means selected from the group consisting of enteral means and parenteral means.
- 21. The method of claim 20 wherein said parenteral means are selected from the group consisting of: intramuscular, intravenous, and subcutaneous means.
- 22. The method of claim 14 wherein said inflammation is associated with a condition selected from the group consisting of: asthma; adult respiratory distress syndrome; atherosclerosis; multiple organ injury syndrome secondary to septicemia; multiple organ injury syndrome secondary to trauma; reperfusion injury of tissue; acute glomerulonephritis; reactive arthritis; dermatosis with acute inflammatory components; a central nervous system inflammatory disorder; thermal injury; hemodialysis; leukapheresis; ulcerative colitis; Crohn's disease; necrotizing enterocolitis; granulocyte transfusion associated syndrome; cytokine-induced toxicity; and atherosclerosis.
- 23. The method of claim 22 wherein said condition is adult respiratory distress syndrome.
- 24. The method of claim 22 wherein said condition is multiple organ injury syndrome secondary to septicemia.
- 25. The method of claim 22 wherein said condition is multiple organ injury syndrome secondary to trauma.
- 26. The method of claim 22 wherein said condition is reperfusion injury of tissue.
- 27. The method of claim 26 wherein said reperfusion injury is reperfusion injury of myocardial tissue.
- 28. The method of claim 22 wherein said condition is acute glomerulonephritis.
- 29. The method of claim 22 wherein said condition is reactive arthritis.
- 30. The method of claim 22 wherein said condition is dermatosis with acute inflammatory components.
- 31. The method of claim 22 wherein said condition is a central nervous system inflammatory disorder.
- 32. The method of claim 31 wherein said central nervous system inflammatory disorder is acute purulent meningitis.
- 33. The method of claim 22 wherein said condition is thermal injury.
- 34. The method of claim 22 wherein said condition is hemodialysis.
- 35. The method of claim 22 wherein said condition is leukapheresis.
- 36. The method of claim 22 wherein said condition is ulcerative colitis.
- 37. The method of claim 22 wherein said condition is Crohn's disease.
- 38. The method of claim 22 wherein said condition is necrotizing enterocolitis.
- 39. The method of claim 22 wherein said condition is granulocyte transfusion associated syndrome.
- 40. The method of claim 22 wherein said condition is cytokine-induced toxicity.
- 41. The method of claim 22 wherein said condition is atherosclerosis.
- 42. A method of treating viral infection which comprises providing to a subject in need of such treatment, an effective amount of a composition comprising the alpha-subunit of MAC-1, or a functional derivative thereof.
- 43. The method of claim 42 wherein said MAC-1 alpha-subunit is provided in association with a beta chain of the CD-18 family.
- 44. The method of claim 42 wherein said viral infection is a rhinoviral infection.
- 45. The method of claim 43 wherein said viral infection is a rhinoviral infection.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 07/235,353; filed on Aug. 23, 1988.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08433801 |
May 1995 |
US |
Child |
08979940 |
Nov 1997 |
US |
Continuations (3)
|
Number |
Date |
Country |
Parent |
08077098 |
Jun 1993 |
US |
Child |
08433801 |
May 1995 |
US |
Parent |
07942056 |
Sep 1992 |
US |
Child |
08077098 |
Jun 1993 |
US |
Parent |
07321239 |
Mar 1989 |
US |
Child |
07942056 |
Sep 1992 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
07235353 |
Aug 1988 |
US |
Child |
07321239 |
Mar 1989 |
US |